Bezafibrate after UDCA improves survival in PBC

Patients with primary biliary cholangitis who received bezafibrate after incomplete response to Ocaliva showed lower risk for death or liver transplant, according to a presenter at the Digital International Liver Congress.“Ursodeoxycholic acid [Ocaliva, Intercept] is a first-line treatment for primary biliary cholangitis. As you know, 20% to 30% of patients exhibit incomplete response to UDCA, resulting in poor outcome including death or liver transplantation. Second-line treatment for PBC has been long awaited for these patients,” Atsushi Tanaka, MD, of Teikyo University SchoolRead More

Share on facebook
Share on twitter
Share on linkedin